TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01922076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT00642187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02748187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBASP
Description: Interpersonal psychotherapy for chronic depression
Study: NCT00349479

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Barrier assessment / interactive educational intervention
Description: Intervention hospitals received a barrier assessment - interactive educational intervention (BA-IEI) which included: on-site barrier assessment, annual stroke champions meetings, stroke center telephone access, quarterly mock stroke codes, and ongoing feedback and education.
Study: NCT00180635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoguanidine
Description: 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoguanidine
Description: 500mg
Study: NCT03868449

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 questions
Description: 3 questions from the AskShareKnow model
Study: NCT03101943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Spirit Nurture (FSN)
Description: The FSN intervention will be conducted over a 6-month period. Participants in the intervention group will receive 6- 45 minute lessons in their home or a private place of their choosing. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices

Intervention type: OTHER
Group type: OTHER
Intervention: Control Program
Description: The control group will receive three home-based lessons with home safety information.Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing.

Intervention type: OTHER
Group type: OTHER
Intervention: Water Delivery
Description: Drinking water will be delivered to the household of each participant (both in the FSN intervention and control groups) from 6 to 9 months postpartum. The amount of water will be determined by the number of children and adults living in the household at the time of water delivery. The first delivery of water will occur at the time of the 6-month evaluation and the last delivery will occur at the time of the 9-month evaluation. Water will be delivered as often as weekly. Those families who do not need weekly water delivery (based on their preference and their usage of the first delivery of water) will receive water less frequently.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Delivery
Description: Drinking water will be delivered to the household of each participant (both in the FSN intervention and control groups) from 6 to 9 months postpartum. The amount of water will be determined by the number of children and adults living in the household at the time of water delivery. The first delivery of water will occur at the time of the 6-month evaluation and the last delivery will occur at the time of the 9-month evaluation. Water will be delivered as often as weekly. Those families who do not need weekly water delivery (based on their preference and their usage of the first delivery of water) will receive water less frequently.
Study: NCT03857022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsa
Description: The EECP therapy was given as a 1-hour session, once daily, for a total of 35 sessions. The daily urine amount, blood pressure, time for taper off positive inotropic agents, length of hospital stay, and will be monitored daily in the hospital stay. Patients will be followed-up if he or she can be released from hospital and the mortality, readmission for heart failure, and 6-minute walking distance will be checked at the end of 6th month. Plasma natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-pro-BNP) levels will be checked at enrollment, day 35, and 6th month.
Study: NCT02010411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolastin (drug)
Description: Outcomes compared to saline or no intervention in each subject.
Study: NCT01519128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Digoxin
Description: Type=exact number, unit=mg, number=0.5, form=tablet, route=oral. Digoxin administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Digoxin
Description: Type=exact number, unit=mg, number=0.5, form=tablet, route=oral. Digoxin administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: TMC278
Description: Type=exact number, unit=mg, number=25, form=tablet, route=oral. TMC278 administered for 16 days, with digoxin administered in the morning on Day 11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: TMC278
Description: Type=exact number, unit=mg, number=25, form=tablet, route=oral. TMC278 administered for 16 days, with digoxin administered in the morning on Day 11.
Study: NCT01448083

Intervention type: OTHER
Intervention: Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.
Description: Each subject will receive a 370 MBq (10 mCi ) (±10%) injection of I- 123 MIBG. Myocardial I-123 MIBG uptake will be quantitatively measured over time via planar imaging acquired at 15 minutes, one, two, four, and at 24 hours (the standard of care time point for NET patient imaging) post I-123MIBG injection.
Study: NCT01643369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Based Compassion Training
Description: Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adult Health Education Curriculum
Description: Eight week training in health and wellness, using a curriculum developed specifically for this study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Attention Training
Description: Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
Study: NCT01234779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin [RO4917838]
Description: 10 mg orally daily, 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin [RO4917838]
Description: 30 mg orally daily, 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 15 mg orally daily, 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally daily, 4 weeks
Study: NCT00180635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoguanidine
Description: 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 2ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 2ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 2ml
Study: NCT04259086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: Intramuscular injection
Study: NCT01850979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: tacrolimus 0,03% eyedrops (olive oil vehicle) every 12 hours for 3 months placebo : olive oil eyedrops every 12 hours for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
Study: NCT03248375

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Segmentectomy
Description: The administration of radioactivity in a branch of an artery of the liver
Study: NCT04357067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lingual brackets
Description: A type of bracket that applied lingual surface of teeth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labial brackets
Description: A type of bracket that applied labial surface of teeth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labial brackets
Description: A type of bracket that applied labial surface of teeth.
Study: NCT03617770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Opt-In
Description: 8-week intervention that includes a wearable sleep tracker, didactic content, smartphone application and counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: 8-week intervention that includes weekly telephone counseling on healthy living.
Study: NCT01137058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U-healthcare service
Description: Public switched telephone network (PSTN)-connected glucometer with U-healthcare system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SMBG group
Description: Glucose control with self monitoring of blood glucose.
Study: NCT01263236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940094
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940094
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT03064698

Intervention type: OTHER
Intervention: Post-partum Doppler ultrasound
Description: Participants will undergo one uterine artery Doppler ultrasound at 6 weeks post-partum.

Intervention type: OTHER
Intervention: Post-partum Doppler ultrasound
Description: Participants will undergo one uterine artery Doppler ultrasound at 6 weeks post-partum.
Study: NCT02528006

Intervention type: DEVICE
Group type: OTHER
Intervention: Type 2 Thyroplasty using Titanium Bridges
Study: NCT01665157

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enimaclin®
Description: Enimaclin Colomil ® (Glico Co., Japan Osaka)，a low-residue diet package for each meal.~The duration of study is one day before colonoscopy.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enimaclin®
Description: Enimaclin Colomil ® (Glico Co., Japan Osaka)，a low-residue diet package for each meal.~The duration of study is one day before colonoscopy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Self-controlled diet
Description: Self-controlled low residue diet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2L PEG-ELS
Description: Normal volume of PEG-ELS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L PEG-ELS
Description: Normal volume of PEG-ELS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low volume 1.5L PEG-ELS
Description: Low volume PEG-ELS
Study: NCT02915757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDOR test
Description: The ElectroDermal Orienting Reactivity (EDOR) specifically is optimized for the detection of electrodermal hyporeactivity.~The EDOR investigation last about 30 min. The EDOR Test Data is sent immediately after each EDOR Test for each Test Person to a Company named EMOTRA for blind analyses. The EDOR Test Report may change the basis for the assessment and a new risk assessment may be needed to be done.~Blood sample and clinical assessment
Study: NCT01057238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Communication System
Description: Regular family meetings once a week, using a standard protocol
Study: NCT03927469

Intervention type: OTHER
Intervention: age, sex, hemiplegic side, stroke duration, First hospitalisation duration (day)
Description: This is a retrospiective descriptive study
Study: NCT02901067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin and Rosuvastatin
Description: Patients assigned to the intervention arm will receive the standard of care anti-coagulation plus the combination experimental drugs (20mg of rosuvastatin daily and 325mg of aspirin) daily either orally or via feeding tube.
Study: NCT04016948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy optical biopsy
Description: In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
Study: NCT02901067

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Aspirin and Rosuvastatin)
Description: Patients assigned to the control group will receive the standard of care anti-coagulation plus identical-looking placebos either orally or via feeding tube.
Study: NCT04664036

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: ultrasound to check for NAFLD according to Saverymuttu criteria

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound
Description: ultrasound to check for NAFLD according to Saverymuttu criteria
Study: NCT04016948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-operative frozen section
Description: In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
Study: NCT03623087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: SIMPLE
Study: NCT04664036

Intervention type: DIAGNOSTIC_TEST
Intervention: elastography
Description: elastography to compare liver stiffness indices

Intervention type: DIAGNOSTIC_TEST
Intervention: elastography
Description: elastography to compare liver stiffness indices

Intervention type: DIAGNOSTIC_TEST
Intervention: controlled attenuation parameter (CAP)
Description: CAP is a non-invasive additive on Fibroscan (trademark) which can quantify hepatic steatosis

Intervention type: DIAGNOSTIC_TEST
Intervention: controlled attenuation parameter (CAP)
Description: CAP is a non-invasive additive on Fibroscan (trademark) which can quantify hepatic steatosis

Intervention type: DIAGNOSTIC_TEST
Intervention: FLI
Description: the FLI is a score panel designed to screen for NAFLD

Intervention type: DIAGNOSTIC_TEST
Intervention: FLI
Description: the FLI is a score panel designed to screen for NAFLD

Intervention type: DIAGNOSTIC_TEST
Intervention: FIB-4
Description: the FIB-4 is a score panel designed to screen for significant fibrosis

Intervention type: DIAGNOSTIC_TEST
Intervention: FIB-4
Description: the FIB-4 is a score panel designed to screen for significant fibrosis

Intervention type: DIAGNOSTIC_TEST
Intervention: NFS
Description: the NFS is a score panel designed to screen for significant fibrosis
Study: NCT03623087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: SIMPLE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16)
Description: SIMPLE
Study: NCT04664036

Intervention type: DIAGNOSTIC_TEST
Intervention: NFS
Description: the NFS is a score panel designed to screen for significant fibrosis
Study: NCT03710382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking epidural
Description: Parturients in spontaneous or induced labor will receive combined spinal-epidural analgesia (CSE) using an infusion of bupivacaine 0.0625% and fentanyl 2 mcg/mL and will be encouraged to walk a minimum of 15 minutes every hour during the first stage of labor.
Study: NCT04418596

Intervention type: RADIATION
Intervention: bi-planer radiography (EOS), Conventional radiography (Hip+pelvis)
Description: low dose radiation medical imaging to visualise the hip joint and lumbo-pelvic complex specifically.

Intervention type: RADIATION
Intervention: bi-planer radiography (EOS), Conventional radiography (Hip+pelvis)
Description: low dose radiation medical imaging to visualise the hip joint and lumbo-pelvic complex specifically.
Study: NCT03660332

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of a liquid meal intraduodenally
Description: Infusion of IL-6/NaCL before a liquid meal intraduodenally
Study: NCT03623087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: SIMPLE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: SIMPLE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: SIMPLE
Study: NCT02241941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Study: NCT03660332

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Infusion of a liquid meal intraduodenally
Description: Infusion of IL-6/NaCL before a liquid meal intraduodenally
Study: NCT04037163

Intervention type: DIAGNOSTIC_TEST
Intervention: Fractional flow reserve, Coronary CT angiography
Description: Coronary CT angiography was performed as part of routine clinical practice for patients with suspected coronary artery disease and the decision to perform coronary CT angiography before invasive angiography was at the judgment of the physicians in charge.
Study: NCT03877601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Topical administration of Bevacizumab-IRDye800CW during the endoscopic procedure.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluorescence endoscopy
Description: Device: Molecular Fluorescence Endoscopy platform A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope.
Study: NCT03884530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor (Brilique) 90
Description: Drug name Brilique 90 ml Drug form tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 75mg
Description: Drug name Aspirin 75 ml Drug form tablet
Study: NCT04814836

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total-etch mode with 35% phosphoric acid (K-ETCHANT) (TE-A group)
Description: 35% phosphoric acid was applied to enamel and dentin for 10 s, washed and dried for 5 s. The universal adhesive, Clearfil Universal Bond Quick (CBQ) was applied to enamel and dentin surfaces with a single-use applicator, then gently air-dried for 5 s without waiting, and light-cured for 10 s.
Study: NCT01532960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: poly-ICLC
Description: poly-ICLC
Study: NCT04814836

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Selective-etch mode with 35% phosphoric acid (K-ETCHANT) (SE-A group)
Description: 35% phosphoric acid was used only on enamel for 10 s, then washed and dried for 5 seconds. Subsequently, the adhesive was applied in a similar manner to the TE-A group.
Study: NCT01532960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9 Peptides from Her-2/neu, CEA, & CTA
Description: 9 synthetic peptides derived from Her-2/neu, CEA \& CTA derived breast cancer proteins.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide-tet
Description: A class II MHC-restricted helper peptide derived from tetanus toxoid protein.
Study: NCT00282399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Decitabine
Study: NCT04814836

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total-etch mode with Er, Cr: YSGG laser (Waterlase MD) (TE-L group)
Description: the enamel margin and dentin surfaces of lesions were irradiated with an Er,Cr:YSGG laser (2780 nm, Waterlase MD, BioLase Technology, Inc., San Clemente, CA). Then the adhesive was applied in a similar manner to the TE-A group.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Selective-etch mode with Er, Cr: YSGG laser (Waterlase MD) (SE-L group).
Description: The laser system was applied in the same way as described in the TE-L group only on enamel surface. Subsequently, the adhesive was applied in the same way as described in the TE-A group.
Study: NCT00282399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Decitabine
Study: NCT04814836

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Self-etch mode Clearfil Universal Bond Quick (Kuraray, Japan) (SE group)
Description: Universal adhesive system (CBQ) was applied to enamel and dentin surfaces without any previous etching. Then gently air-dried for 5 s without waiting, and light-cured for 10 s.
Study: NCT04060875

Intervention type: DEVICE
Intervention: Karuna Labs Virtual Reality Software
Description: The subjects will engage in the three therapeutic modules: laterality, motor imagery, and 'mirroring.' The decision of which module to employ will be based on the subject's readiness and comfort on a case-by-case basis. A subject visit can be expected to last 40 minutes, with enough time to complete PHQ-9, and to accustom to the virtual reality setup by playing in a non-therapeutic virtual environment should they choose to do so. Time in the virtual reality is expected to last approximately 20 minutes per session.
Study: NCT01892059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Segmental artery clamping
Description: Laparoscopic partial nephrectomy with segmental artery clamping will be performed for patients enrolled in this group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Main renal artery clamping
Description: Laparoscopic partial nephrectomy with main renal artery clamping technique will be performed for patients enrolled in this group.
Study: NCT04216030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fe IP meal labelled with Fe-58
Description: 500 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control OFSP meal labelled with Fe-57
Description: 500 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
Study: NCT02231710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 and Rimiducid
Description: Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by Rimiducid infusion on day 7